Workflow
天坛生物(600161) - 2015 Q1 - 季度财报
BTBPBTBP(SH:600161)2015-05-28 16:00

Financial Performance - Operating revenue for the current period was CNY 354,014,490.93, representing a decrease of 22.68% year-on-year[6] - Net profit attributable to shareholders of the listed company was CNY 12,098,387.93, down 87.24% from the previous year[6] - Basic earnings per share decreased to CNY 0.02, down 87.24% from CNY 0.18 in the same period last year[7] - The net profit after deducting non-recurring gains and losses was CNY 8,895,153.21, a decrease of 90.47% year-on-year[6] - Total profit decreased by 64.84% from CNY 138,422,049.47 to CNY 48,674,828.58, primarily due to a 22.94% decline in sales revenue[17] - The net profit fell by 71.37% from CNY 114,549,067.17 to CNY 32,798,360.67, reflecting the overall decrease in total profit[17] - The company reported a total equity of CNY 2,250,430,970.13, up from CNY 2,217,632,609.46 at the beginning of the year[26] - The company's net profit for Q1 2015 is not explicitly stated, but the decrease in revenue and costs suggests a focus on improving profitability[31] - The total profit for Q1 2015 was -¥52,587,810.59, a stark contrast to the profit of ¥41,620,939.56 in the same period last year[34] Cash Flow - The net cash flow from operating activities was CNY -3,572,079.63, an improvement of 95.83% compared to the same period last year[6] - The net cash flow from operating activities improved by 95.83%, increasing from CNY -85,582,183.02 to CNY -3,572,079.63, attributed to reduced tax payments[16] - The company's cash flow from investment activities improved by 35.09%, from CNY -168,753,016.03 to CNY -109,544,467.93, due to reduced investment in the Yizhuang vaccine industrial base project[17] - The cash inflow from operating activities was 51,104,233.77 RMB, slightly up from 50,072,725.07 RMB in the previous period[41] - The net cash flow from investing activities was -94,640,962.61 RMB, compared to -196,348,096.37 RMB in the previous period, showing an improvement in investment cash flow[41] - The net increase in cash and cash equivalents was -214,740,473.44 RMB, compared to 69,059,165.90 RMB in the previous period, indicating a significant cash outflow[42] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,003,011,718, a decrease of 0.21% compared to the end of the previous year[6] - Current liabilities totaled CNY 2,475,596,607.07, a slight decrease from CNY 2,550,969,630.67 at the beginning of the year[26] - Non-current liabilities amounted to CNY 1,276,984,140.80, an increase from CNY 1,246,846,177.39 at the start of the year[26] - Total assets as of March 31, 2015, were CNY 5,028,321,036.92, down from CNY 5,060,258,029.49 at the beginning of the year[29] - The company's cash and cash equivalents decreased to CNY 615,861,646.07 from CNY 826,228,256.53[27] - Inventory increased to CNY 229,155,237.40 from CNY 179,718,293.10, indicating potential growth in production or sales[27] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,309[10] - The largest shareholder, China National Biotechnology Group Corporation, held 53.30% of the shares[10] Government Support - The company received government subsidies amounting to CNY 4,106,573.83, primarily related to research funding[8] Cost Management - The company's prepaid expenses increased by 70.35% from CNY 13,147,249.47 to CNY 22,396,033.75, primarily due to increased advance payments for materials[13] - Other receivables rose by 62.82% from CNY 25,452,349.25 to CNY 41,442,624.21, mainly due to increased performance guarantees and energy fee borrowings[13] - The company is focusing on cost management, as indicated by the reduction in operating costs despite a decline in revenue[31] - The company experienced a decrease in management expenses to ¥48,706,120.75 from ¥75,677,291.59 in the previous year, indicating a focus on reducing overhead costs[34] - The company reported a decrease in sales expenses to ¥8,869,458.95 from ¥8,507,373.32 in the previous year, reflecting cost management efforts[34] Financial Expenses - The company reported a 496.32% increase in financial expenses, rising from CNY 4,470,880.04 to CNY 26,660,876.81, mainly due to interest expenses being recognized after the completion of the Yizhuang project[17] - The financial expenses for Q1 2015 were ¥23,080,823.92, a significant increase from ¥66,626.05 in the previous year[34] Business Strategy - The company is actively working on business integration and restructuring to mitigate competition within its group, aiming to enhance operational efficiency and protect investor interests[19] - The company anticipates continued increases in depreciation and interest expenses as construction projects transition to fixed assets, impacting future profitability[20]